SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Aeluma, Inc. engages in developing semiconductors for sensing, communication, and computing applications. The firm is also involved in manufacturing devices using compound semiconductor materials on large-diameter substrates that are commonly used to manufacture mass market microelectronics. The company was founded by Jonathan Klamkin and Lee McCarthy on February 28, 2019 and is headquartered in Goleta, CA.

Aeluma Inc

Aeluma is trending as investors weigh its potential for massive growth in silicon photonics against the execution risks associated with its transition from early-stage government contracts to commercial-scale manufacturing. Community sentiment is sharply divided between those bullish on its proprietary 300mm wafer technology as a high-reward play and those skeptical of its current revenue levels and recurring share offerings.

Revolution Medicines, Inc. is a clinical-stage precision oncology company, which engages in developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanisms for patients which are dependent on the RAS and mTOR pathway. The company was founded by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano and Michael Fischbach in October 2014 and is headquartered in Redwood City, CA.

Revolution Medicines Inc

Revolution Medicines is gaining significant momentum as investors digest recent FDA Orphan Drug Designations and progress in late-stage Phase 3 clinical trials for its pancreatic cancer therapy. The community is actively discussing the stock's potential for a major re-rating, with analysts increasingly highlighting the company's robust pipeline and strategic importance in targeted oncology.

The Goldman Sachs Group, Inc. engages in the provision of financial services. It operates through the following business segments: Global Banking and Markets, Asset and Wealth Management, and Platform Solutions. The Global Banking and Markets segment includes investment banking, global investments, and equity and debt investments. The Asset and Wealth Management segment relates to the direct-to-consumer banking business which includes lending, deposit-taking, and investing. The Platform Solutions segment includes consumer platforms such as partnerships offering credit cards and point-of-sale financing, and transaction banking. The company was founded by Marcus Goldman in 1869 and is headquartered in New York, NY.

Goldman Sachs Group, Inc.

Goldman Sachs is trending due to the resignation of its top lawyer amid revelations of ongoing ties to Jeffrey Epstein, triggering a sharp decline in share price. Investors are also closely monitoring the bank's exposure to volatile credit markets and broader concerns regarding institutional stability during a period of geopolitical uncertainty.

VanEck ETF Trust - VanEck Semiconductor ETF

VanEck Semiconductor ETF

The VanEck Semiconductor ETF is experiencing intense volatility and heightened scrutiny as traders debate whether current valuation levels represent a sustainable AI-driven growth cycle or an overheated bubble. The community is actively tracking a sharp divergence between high-flying hardware momentum and a struggling software sector, while aggressive options activity and short-dated put sweeps suggest that institutional players are bracing for significant downside risks.

Lightwave Logic, Inc. is a development stage company which engages in the commercialization of electro-optic photonic devices. The firm offers the P2ICTM technology platform which uses in-house proprietary organic polymers. Its products include electro-optical modulation devices and proprietary polymer photonic integrated circuits. The company was founded on June 24, 1997 and is headquartered in Englewood, CO.

Lightwave Logic Inc

Lightwave Logic is seeing heavy retail and institutional interest as investors bet on the companys electro-optic polymer technology as a scalable solution for AI data centers. The community is actively debating the transition from R&D to foundry-integrated manufacturing, with recent partnerships and expectations of upcoming tape-out results driving volatility and ongoing speculation about potential major industry acquisitions.

Applied Optoelectronics, Inc. engages in the design and manufacture of optical communications products. Its products include optical devices, such as laser diodes, photodiodes, related modules and circuitry, and equipment for applications in fiber-to-the-home, cable television, point to point communications, and wireless. The company was founded by Chih Hsiang Lin on February 28, 1997 and is headquartered in Sugar Land, TX.

Applied Optoelectronics Inc

Applied Optoelectronics is experiencing intense investor interest and volatility driven by its role in the AI infrastructure supply chain and significant follow-on orders for optical transceivers. While bulls highlight rapid revenue scaling and demand in the photonics sector, the community remains sharply divided, with active debates centered on whether recent parabolic price moves are justified by fundamentals or represent a speculative bubble ripe for a short squeeze.

IDEAYA Biosciences, Inc. engages in the research and development of oncology-focused precision medicine. The firm focuses on the targeted therapeutics for patients selected using molecular diagnostics. Its product candidate, IDE196, is a protein kinase C inhibitor for genetically defined cancers having GNAQ and GNA11 gene mutations. The company was founded by Yujiro S. Hata and Jeffrey Hager in June 2015 and is headquartered in South San Francisco, CA.

Ideaya Biosciences Inc

Ideaya Biosciences is surging following positive Phase 2/3 trial results for its metastatic uveal melanoma treatment, which significantly improved progression-free survival compared to standard therapies. Investors and the community are actively debating the potential for an accelerated FDA filing, while also closely watching for future pipeline updates and high institutional interest.

RaveDAO is a global community uniting music, technology, and purpose. Since their first sold-out event at Dubai 2024, they have expanded across Europe, the Middle East, North America, and Asia, hosting world-class experiences with over 100,000 total attendees and 3,000+ attendees for each event.  RaveDAO has worked with top-tier artists like Vintage Culture, Don Diablo, Chris Avantgarde, Lilly Palmer, MORTEN, Bassjackers, and GENESI and has support from Binance, OKX, Bitget, and Polygon. RaveDAO is redefining live entertainment in Web3 and has active partnerships with 1001Tracklists, AMF, and Warner Music.  Beyond the dance floor, RaveDAO channels energy and attention toward impact. In 2025 alone, proceeds from its events helped restore sight to 400+ cataract patients in Nepal and fund over 150 meditation programs across the U.S.

RaveDAO

RaveDAO is experiencing significant market interest driven by a combination of high trading volume, a short squeeze, and momentum following its expansion and integration with the USD1-denominated ecosystem. While some community members are actively debating the token's long-term utility and governance, others are focused on its rapid price action and speculative potential as a trending Web3 entertainment protocol.

Maulcoin

Maulcoin is trending as a community-driven, Star Wars-themed meme coin, with supporters actively lobbying for a price chart on major platforms while sharing their experiences with holding through volatility. The community remains focused on collective buying efforts and long-term holding to drive up market capitalization, frequently highlighting the project's growth and their commitment to building a lasting cultural presence.

Spyre Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases. Its product, Pegzilarginase, is in a Phase 3 pivotal trial for the treatment of Arginase 1 Deficiency. The company was founded by George Georgiou and David G. Lowe on December 16, 2013 and is headquartered in Waltham, MA.

Spyre Therapeutics Inc.

Aeglea BioTherapeutics Inc

Spyre Therapeutics is seeing significant investor interest following positive clinical data for its SPY001 program, with the community actively discussing the company's multi-pathway platform approach and its potential to disrupt the IBD market. While some investors are focused on the long-term potential of its upcoming pipeline milestones, others remain cautious regarding the risks typically associated with clinical-stage biotechnology companies.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Zhihu Inc. Sponsored ADR (NYSE:ZH) Short Interest Up 19.9% in March

Zhihu Inc. Sponsored ADR (NYSE:ZH - Get Free Report) was the recipient of a significant increase in short interest in the month of March. As of March 13th, there was short interest totaling 1,127,389...

Zhihu (NYSE:ZH) Stock Rating Lowered by Wall Street Zen

Wall Street Zen cut Zhihu from a "hold" rating to a "sell" rating in a research report on Saturday...

Zhihu (NYSE:ZH) Releases Quarterly Earnings Results, Misses Expectations By $0.30 EPS

Zhihu (NYSE:ZH - Get Free Report) posted its earnings results on Wednesday. The company reported ($0.38) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by...

Zhihu Q4 Earnings Call Highlights

Zhihu (NYSE:ZH) executives highlighted a milestone shift to full-year non-GAAP profitability in 2025, alongside growing user engagement and a strategy to deepen AI integration across both the community and commercialization efforts, according to remarks on the company's fourth-quarter and full-year...

Zhihu (ZH) Expected to Announce Earnings on Wednesday

Zhihu (NYSE:ZH) will be releasing its Q4 2025 earnings before the market opens on Wednesday, April 1. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-4-1-zhihu-inc-stock...

Zhihu Inc. Sponsored ADR (NYSE:ZH) Short Interest Update

Zhihu Inc. Sponsored ADR (NYSE:ZH - Get Free Report) was the recipient of a large growth in short interest during the month of February. As of February 27th, there was short interest totaling 940,021...

Zhihu (NYSE:ZH) Trading Down 4.1% - Should You Sell?

Zhihu (NYSE:ZH) Stock Price Down 4.1% - Here's Why...

Zhihu Inc. Sponsored ADR (NYSE:ZH) Short Interest Down 18.4% in December

Zhihu Inc. Sponsored ADR (NYSE:ZH - Get Free Report) was the target of a large decline in short interest in December. As of December 31st, there was short interest totaling 656,456 shares, a decline...

Zhihu (NYSE:ZH) Upgraded at Wall Street Zen

Wall Street Zen upgraded Zhihu from a "sell" rating to a "hold" rating in a research report on Sunday...

Zhihu (NYSE:ZH) Rating Lowered to Sell at Wall Street Zen

Wall Street Zen lowered shares of Zhihu from a "hold" rating to a "sell" rating in a report on Saturday...

Zhihu, Inc. operates as a Q&A online content community. It content fields include Internet technology, commerce, film, television, fashion and culture. The company was founded by Yuan Zhou in 2010 and is headquartered in Beijing, China.

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	-$0.01	-$0.14	-1165.50%	MISSED
Q3 '25	--	-$0.08	--	N/A
Q2 '25	-$0.02	$0.12	784.89%	BEAT
Q1 '25	-$0.03	-$0.02	46.48%	BEAT
Q4 '24	--	$0.14	--	N/A

ZH
Zhihu Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q4 '25

Historical Earnings

Latest ZH News

ZHZhihu Inc.